^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Solid Tumor
    Drug:Dupert (fulzerasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

    Excerpt:
    ...Have histologically or cytologically confirmed advanced KRAS G12C-mutated NSCLC....
    Trial ID:
    NCT05756153
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

    Excerpt:
    ...- Pathologically diagnosed, previously treated, advanced tumor with KRAS p.G12C mutation...
    Trial ID:
    NCT05005234
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

    Excerpt:
    ...have documentation of KRAS G12C mutation 3....
    Trial ID:
    NCT05497336
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

    Published date:
    05/26/2022
    Excerpt:
    IBI351(GFH925) was well-tolerated without unanticipated adverse events across all doses explored in pts with advanced solid tumors harboring the KRAS p.G12C mutation.
    Trial ID:
    NCT05005234